問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of General Internal Medicine

Division of Otolaryngology

Division of Hematology & Oncology

Division of Thoracic Medicine

National Taiwan University Hospital Hsin-Chu Branch (在職)

Division of Hematology & Oncology

National Taiwan University Cancer Center (在職)

Division of Hematology & Oncology

更新時間：2023-09-19

廖斌志
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

231Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

廖斌志

List

338Cases

2019-01-01 - 2028-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2020-06-01 - 2024-05-31

Phase I

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2018-04-30 - 2020-04-30

Phase I

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2024-04-01 - 2028-01-31

Phase I

Active
A Phase 1/2a Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of DB-1311 in Subjects with Advanced/Metastatic Solid Tumors

  • Condition/Disease

    Advanced/Metastatic Solid Tumors

  • Test Drug

    injection

Participate Sites
10Sites

Not yet recruiting1Sites

Recruiting8Sites

Terminated1Sites

2020-07-01 - 2022-01-17

Phase I

A Phase 1/1b First-in-human Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR439459 Administered Intravenously as Monotherapy and in Combination With Cemiplimab in Adult Patients With Advanced Solid Tumors

  • Condition/Disease

    Malignant Solid Tumor

  • Test Drug

    SAR439459

Participate Sites
3Sites

Recruiting1Sites

Terminated2Sites

2018-06-01 - 2022-11-15

Phase I

A Phase 1/2 Open-label, Multi-center, Safety, Preliminary Efficacy and Pharmacokinetic (PK) Study of Isatuximab (SAR650984) in Combination With Atezolizumab or Isatuximab Alone in Patients With Advanced Malignancies

  • Condition/Disease

    Advanced Malignancies

  • Test Drug

    Isatuximab

Participate Sites
7Sites

Not yet recruiting1Sites

Recruiting5Sites

趙毅
Taipei Veterans General Hospital

Division of Hematology & Oncology

余明隆
Kaohsiung Municipal Gangshan Hospital

未分科

2015-07-01 - 2020-12-31

Phase II

Multicenter, open-label, single arm, Phase II study in advanced non-small cell lung cancer；Subtitle:A multicenter, open-label, single arm Phase II study to evaluate safety and efficacy of ONO-4538 in stage IIIB/IV or recurrent non-small cell lung cancer patients who are unsuited to radical radiotherapy and resistant to a platinum-base chemotherapeutic regimen.

  • Condition/Disease

    stage IIIB/IV or recurrent non-small cell lung cancer

  • Test Drug

    Opdivo®

Participate Sites
10Sites

Not yet recruiting1Sites

Terminated8Sites

陳育民
Taipei Veterans General Hospital

Division of Thoracic Medicine

楊政達
Linkou Chang Gung Medical Foundation

Division of Thoracic Medicine

2015-10-22 - 2019-12-31

Phase III

A Phase III Randomized, Open-label, Multi-center, Global Study of MEDI4736 in Combination with Tremelimumab versus Standard of Care in the Treatment of First-line Recurrent or Metastatic Squamous Cell Head and Neck Cancer Patients

  • Condition/Disease

    Squamous Cell Head and Neck Cancer

  • Test Drug

    MEDI4736; Tremelimumab

Participate Sites
8Sites

Terminated7Sites

謝清昀
China Medical University Hospital-Taipei

未分科

楊慕華
Taipei Veterans General Hospital

Division of Otolaryngology

2017-08-24 - 2019-09-30

Phase III

A Phase III, Randomized, Multicenter,Open-Label, Comparative Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for the First-Line Treatment in Patients With Extensive Disease Small-Cell Lung Cancer (SCLC) (CASPIAN)

  • Condition/Disease

    Small-Cell Lung Cancer (SCLC)

  • Test Drug

    Durvalumab; Tremelimumab

Participate Sites
11Sites

Terminated10Sites

邱昭華
Taipei Veterans General Hospital

Division of Hematology & Oncology

夏德椿
China Medical University Hospital-Taipei

未分科

2018-07-24 - 2021-01-05

Phase I

A Multi-Center, Phase 1, Open-Label, Dose-Escalation Study of ABBV-428, an Immunotherapy in Subjects With Advanced Solid Tumors

  • Condition/Disease

    Advanced Solid Tumors

  • Test Drug

    ABBV-428

Participate Sites
2Sites

Terminated1Sites

1 26 27 28 29 30 34
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB